Obagi C-CLARIFYING SERUM
Contains 4% hydroquinone to reduce hyperpigmentation, such as dark spots and melasma, for a lighter, more even skin tone. Also contains 10% L-ascorbic acid (Vitamin C) to help defend against free radicals and address the appearance of aging skin. Valid prescription required. Please see Prescribing Information.
Active Ingredient:
4% Hydroquinone
Key Ingredient:
10% L-ascorbic Acid
Important Safety Information for Obagi-C Rx C-Clarifying Serum and C-Therapy Night Cream
(contains 4% hydroquinone)
CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
Contains 4% hydroquinone to reduce hyperpigmentation, such as dark spots and melasma, for a lighter, more even skin tone. Also contains 10% L-ascorbic acid (Vitamin C) to help defend against free radicals and address the appearance of aging skin. Valid prescription required. Please see Prescribing Information.
Active Ingredient:
4% Hydroquinone
Key Ingredient:
10% L-ascorbic Acid
Important Safety Information for Obagi-C Rx C-Clarifying Serum and C-Therapy Night Cream
(contains 4% hydroquinone)
CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
Contains 4% hydroquinone to reduce hyperpigmentation, such as dark spots and melasma, for a lighter, more even skin tone. Also contains 10% L-ascorbic acid (Vitamin C) to help defend against free radicals and address the appearance of aging skin. Valid prescription required. Please see Prescribing Information.
Active Ingredient:
4% Hydroquinone
Key Ingredient:
10% L-ascorbic Acid
Important Safety Information for Obagi-C Rx C-Clarifying Serum and C-Therapy Night Cream
(contains 4% hydroquinone)
CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
